Q1 2019 Earnings Estimate for Spring Bank Pharmaceuticals Inc (SBPH) Issued By William Blair

Share on StockTwits

Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) – Analysts at William Blair lifted their Q1 2019 earnings estimates for shares of Spring Bank Pharmaceuticals in a note issued to investors on Monday, March 11th. William Blair analyst Y. Xu now anticipates that the company will post earnings per share of ($0.43) for the quarter, up from their previous forecast of ($0.51). William Blair also issued estimates for Spring Bank Pharmaceuticals’ Q2 2019 earnings at ($0.43) EPS, Q3 2019 earnings at ($0.43) EPS, Q4 2019 earnings at ($0.44) EPS, FY2019 earnings at ($1.72) EPS, Q1 2020 earnings at ($0.53) EPS, Q2 2020 earnings at ($0.60) EPS, Q3 2020 earnings at ($0.66) EPS, Q4 2020 earnings at ($0.73) EPS and FY2020 earnings at ($2.52) EPS.

Spring Bank Pharmaceuticals (NASDAQ:SBPH) last announced its quarterly earnings results on Monday, March 11th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.17.

Several other brokerages also recently issued reports on SBPH. Chardan Capital set a $45.00 price target on Spring Bank Pharmaceuticals and gave the company a “buy” rating in a report on Friday, November 30th. Cantor Fitzgerald set a $34.00 target price on Spring Bank Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, December 7th. Finally, Zacks Investment Research downgraded Spring Bank Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Spring Bank Pharmaceuticals has an average rating of “Buy” and an average target price of $33.00.

Shares of Spring Bank Pharmaceuticals stock opened at $10.44 on Thursday. Spring Bank Pharmaceuticals has a 1 year low of $8.14 and a 1 year high of $15.73. The firm has a market cap of $172.09 million, a price-to-earnings ratio of -5.58 and a beta of 0.80.

Institutional investors and hedge funds have recently bought and sold shares of the company. Rhumbline Advisers acquired a new stake in shares of Spring Bank Pharmaceuticals during the third quarter worth $122,000. Blair William & Co. IL acquired a new stake in shares of Spring Bank Pharmaceuticals during the third quarter worth $123,000. JPMorgan Chase & Co. lifted its holdings in shares of Spring Bank Pharmaceuticals by 464.0% during the third quarter. JPMorgan Chase & Co. now owns 12,712 shares of the company’s stock worth $153,000 after buying an additional 10,458 shares in the last quarter. Pegasus Asset Management Inc. acquired a new stake in shares of Spring Bank Pharmaceuticals during the fourth quarter worth $195,000. Finally, Dimensional Fund Advisors LP acquired a new stake in shares of Spring Bank Pharmaceuticals during the fourth quarter worth $206,000. 43.18% of the stock is owned by institutional investors.

About Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using small molecule nucleic acid hybrid (SMNH) chemistry platform. The company's lead SMNH product candidate is inarigivir soproxil, for the treatment of chronic hepatitis B virus (HBV).

Featured Story: Net Asset Value

Earnings History and Estimates for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.